T&R Biofab티앤알바이오팹
246710 · KOSDAQ · ₩246710 · 티앤알바이오팹
₩1,906▼ ₩34 (1.75%)End-of-day · Oct 28, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 31.3% | 25.5% | 43.7% | 20.7% | 26.8% | −6.6% |
| Operating margin | −16.5% | −33.6% | −272.9% | −244.7% | −224.1% | −316.9% |
| Net margin | −84.7% | −118.5% | −157.6% | −258.1% | −179.6% | −342.6% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +21.4% | +453.3% | −6.3% | −9.7% | +77.9% | — |
| Operating income growth | +40.2% | +31.9% | −4.5% | +1.3% | −25.8% | — |
| Net income growth | +13.3% | −316.1% | +42.8% | −29.8% | +6.7% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −117.2% | −127.1% | −27.7% | −38.1% | −25.5% | −26.6% |
| Return on assets | −29.9% | −33.4% | −7.7% | −15.3% | −13.1% | −13.5% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 337.4% | 255.6% | 306.6% | 220.0% | 93.4% | 97.2% |
| Net debt to equity | 111.2% | 79.3% | 109.2% | 7.3% | −38.4% | −54.8% |
| Current ratio | 33.1% | 132.4% | 64.4% | 113.0% | 160.9% | 3,810.3% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: T&R Biofab / 티앤알바이오팹 / 246710 / KRX:246710
Source: KRX statistical information